Selecting and Characterizing Drug-Resistant Hepatitis C Virus Replicon

  • Inge Vliegen
  • Leen Delang
  • Johan Neyts
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1030)

Abstract

The current standard of care (SOC) for hepatitis C virus (HCV) genotype 1-infected patients consists of telaprevir or boceprevir in addition to pegylated interferon and ribavirin treatment. Other selective inhibitors of HCV replication are being developed. Drug pressure may, depending on the class of inhibitors, (rapidly) select for drug-resistant variants. Here we describe four different approaches to select in vitro for drug-resistant HCV subgenomic replicons.

Key words

Drug resistance HCV Replicon Genotyping Phenotyping 

References

  1. 1.
    Simmonds P (2004) Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 85(Pt 11):3173–3188PubMedCrossRefGoogle Scholar
  2. 2.
    Le Pogam S, Seshaadri A, Kosaka A et al (2008) Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J Antimicrob Chemother 61(6):1205–1216PubMedCrossRefGoogle Scholar
  3. 3.
    Kuntzen T, Timm J, Berical A et al (2008) Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48(6):1769–1778PubMedCrossRefGoogle Scholar
  4. 4.
    Delang L, Vliegen I, Leyssen P, Neyts J (2012) In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors. J Hepatol 56(1):41–48PubMedCrossRefGoogle Scholar
  5. 5.
    Delang L, Vliegen I, Froeyen M, Neyts J (2011) Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication. Antimicrob Agents Chemother 55(9):4103–4113PubMedCrossRefGoogle Scholar
  6. 6.
    Lohmann V, Korner F, Koch J et al (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285(5424):110–113PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  • Inge Vliegen
    • 1
  • Leen Delang
    • 1
  • Johan Neyts
    • 1
  1. 1.Rega Institute for Medical ResearchLeuvenBelgium

Personalised recommendations